Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 14/20 | 0.45 |
| ▸ | CA1 | P00915 | 12/20 | 0.45 |
| ▸ | CA2 | P00918 | 12/20 | 0.45 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PLEC | Q15149 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2755000 | 0.89 | USP2 (0.68) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL7973011 | 0.88 | USP2 (0.51) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL10060277 | 0.81 | POLB (0.59) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL10098714 | 0.80 | USP2 (0.76) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL12637546 | 0.80 | USP2 (0.57) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL14089620 | 0.78 | CA9 (0.55) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL10014172 | 0.78 | CA9 (0.56) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL12039540 | 0.78 | USP2 (0.55) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL14173524 | 0.78 | USP2 (0.72) | USP2L3MBTL1CA9CA1CA2 | |
| SCHEMBL16731601 | 0.77 | USP2 (0.50) | USP2L3MBTL1CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987379-B2 | Molecular probes for imaging of myelin | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-9555130-B2 | Compositions and methods for in vivo imaging of myelin in the peripheral nervous system | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-01-31 | — | — | US | disclosed |
| EP-1810976-B1 | BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND USE THEREOF | FUJIFILM CORP (JP) | 2014-08-27 | — | — | EP | disclosed |
| US-20140079635-A1 | MOLECULAR PROBES FOR DETECTING LIPID COMPOSITION | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-03-20 | — | — | US | disclosed |
| US-20120093727-A1 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING OF MYELIN IN THE PERIPHERAL NERVOUS SYSTEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-19 | — | — | US | disclosed |
| US-20110189090-A1 | MOLECULAR PROBES FOR IMAGING OF MYELIN | WANG YANMING | 2011-08-04 | — | — | US | disclosed |
| US-20100221180-A1 | IN VIVO IMAGING OF MYELINATION | WANG YANMING | 2010-09-02 | — | — | US | disclosed |
| US-20090123373-A1 | AMYLOID-IMAGING AGENTS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2009-05-14 | — | — | US | disclosed |
| EP-1810976-A1 | BENZONAPHTHACENEGLYCOSIDE DERIVATIVE AND USE THEREOF | FUJIFILM Corporation (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221180-A1 | IN VIVO IMAGING OF MYELINATION | MAG, PMP22, MYT1 | USP2 1401/4885L3MBTL1 1202/4885CA9 4486/4885 |
| US-20140079635-A1 | MOLECULAR PROBES FOR DETECTING LIPID COMPOSITION | MAG, FABP7, PMP22 | USP2 1886/4885L3MBTL1 2999/4885CA9 3400/4885 |
| US-20110189090-A1 | MOLECULAR PROBES FOR IMAGING OF MYELIN | MAG, MYT1, PMP22 | USP2 1479/4885L3MBTL1 2119/4885CA9 2671/4885 |
| US-20090123373-A1 | AMYLOID-IMAGING AGENTS | APBA1, APP, MAPT | USP2 2090/4885L3MBTL1 1864/4885CA9 1710/4885 |
| US-20120093727-A1 | COMPOSITIONS AND METHODS FOR IN VIVO IMAGING OF MYELIN IN THE PERIPHERAL NERVOUS SYSTEM | PMP22, MAG, MYT1 | USP2 1402/4885L3MBTL1 2045/4885CA9 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.